Lupin Limited, a global pharmaceutical company, has entered into an exclusive agreement with Gan&Lee Pharmaceuticals of China to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. Bofanglutide is a fortnightly treatment for type 2 diabetes and weight management in overweight and obese adults, offering a reduced injection frequency compared to existing weekly GLP-1 therapies. Clinical data shows that the drug delivers comparable or better weight loss and glycaemic control outcomes, with a safety and tolerability profile consistent with the GLP-1 class.
The agreement strengthens Lupin’s metabolic health portfolio and marks its entry into the obesity treatment segment. India faces a significant burden of metabolic diseases, with an estimated 90 million adults living with diabetes and 50 million classified as obese. The convenience of a fortnightly dosing regimen may improve treatment adherence for patients requiring long-term therapy. Lupin’s Managing Director, Nilesh Gupta, commented that the agreement reflects the company’s commitment to expanding access to innovative therapies for chronic metabolic conditions.
The partnership also aligns with Gan&Lee Pharmaceuticals’ strategy to expand globally and bring its innovations to new markets. The company is a leading insulin manufacturer in China and has received regulatory approvals in multiple international markets. Lupin Limited, headquartered in Mumbai, operates in over 100 markets worldwide, with a strong presence in India and the United States. The company manufactures a range of products, including branded and generic formulations, complex generics, biotechnology products, and APIs, across 15 manufacturing sites and seven research centers globally.
The agreement is expected to benefit patients in India, where there is a growing need for effective treatments for metabolic diseases. With its strong presence in the Indian market, Lupin is well-positioned to commercialize Bofanglutide and make it accessible to patients who need it. The partnership between Lupin and Gan&Lee Pharmaceuticals is a significant development in the field of metabolic health and is expected to have a positive impact on the lives of millions of people in India and beyond.